TCTR20180920002进行中（未招募）4 期
Clinical outcomes of palbociclib plus letrozole compared to letrozole alone in Thai hormonal receptor positive advanced breast cancer
Thai Society of Clinical Oncology0 个研究点目标入组 100 人开始时间: 2018年9月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20 Years 至 90 Years（—）
- 性别
- Female
入选标准
- •1.metastatic breast cancer, ER+ve,Her2 -ve
- •2.postmenopausal state
- •3.measurable lesion
排除标准
- •1.progression of cancer during adjuvant aromatase inhibitor or less than 1 year after completion of such treatment
- •2.contraindication for treatment with palbociclib
研究者
相似试验
已完成
3 期
Study of Palbociclib taken together with letrozole for treatment of Post-Menopausal Women with Advanced Breast CancerCTRI/2017/03/008034Pfizer Limited100
进行中（未招募）
1 期
Treatment with Letrozol and Palbociclib combination in early Breast Cancer HR(+) / HER2(-)Early HR(+)/HER2(-) Breast CancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001702-28-ESMedica Scientia Innovation Research (MEDSIR)67
已完成
2 期
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerBreast CancerNCT03628066NSABP Foundation Inc24
尚未招募
2 期
Palbociclib plus letrozole treatment for women ovarian cancerRBR-8k2928atin American Cooperative Oncology Group
招募中
2 期
Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer-multi-institutional retrospective study -KBCOG-14ER-positive HER2-negative advanced breast cancerJPRN-UMIN000036224Kobe Breast Cancer Oncology Group200